<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>心血管基本问题</title><link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed=1Vuepj4z_tesaaxkwjxbogotaabxd6u-nvu8003krcpqppqpqpqpq8ylqc-＆utm_contj4z_z_z_z_ tesaaxbog n3 v = 2.18.0.post9+e462414＆utm_medium = rss＆utm_source = Chrome＆ utm_campaign = PubMed-2＆ff = 20250205151245＆fc = 20230708114047<description>心血管田径：PubMed的最新结果</description><atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;utm_medium=rss&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;ff=20250205151245&amp;fc=20230708114047" rel="self"></atom:link><docs> http://www.rsboard.org/rss-specification</docs><generator> PubMed RSS提要（2.18.0.post9+E462414）</generator><language> en</language><lastbuilddate>星期三，2025年2月5日20:12:47 +0000</lastbuilddate><pubDate> Wed, 05 Feb 2025 06:00:00 -0500</pubDate><ttl> 120</ttl><item><title>南非的减少立法和尿钠和血压</title><link/>https://pubmed.ncbi.nlm.nih.gov/39908059/？ 708114047＆ff = 20250205151245＆v = 2.18.0.post9+e462414<description>结论和相关性：在这项队列研究中，南非限制了13种加工食品中的钠，在南非农村地区的24HRNA排泄中降低了这些结果。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">重要性：与降低血压相关的饮食盐均未衡量这些法律的影响。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：确定加工食品中的Ifrican限制性钠含量与钠龙的降低有关。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">设计，环境和参与者：Haalsi（非洲：基于离子的队列研究：40岁或以上的成年人从居住在南非的农村Mpumalanga Provinger中随机选择的成年人中。这项研究结合了3次数据（2014年） /2015、2018/2019和2021/2022）来自Haalsi研究，以检查dium（24HRNA）的排泄物在强制性钠法规后的基于人群的队列中发生了变化。 2023年至2024年。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">暴露：2013年提出的南非法规，该法规在2019年的13个加工食品类别中，每100毫克OFOD PARUCT的LEDUMUM钠数量减少了25％至80％。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">主要结果和措施：使用Intersalt估计估计估计估计估计估计估计估计估计估计估计估计估计估计估计估计估计估计估计估计估计估计估计估计估计估计估计估计估计估计估计估计估计估计的估计估计，从而估计了估计估计估计M的估计估计，从而估计了估计估计M的估计估计，从而估计了24HRNA。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在4059名或40岁以上的成年人中，平均年龄（SD）年龄为62.43岁（13.01），而24HRNA的总体平均值（SD）为3.08 g（0.78）。在前2波之间，平均24HRNA排泄为0.22 g（95％CI，-0.27至-0.17; p &lt;.001），第一个降低-0.28至-0.18；第三波。在所有3个波中，较大的限制都限于样品（-0.26 Aves 2和3与Wave 1相比）。 1.96; p = .00）在系统血压中。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论和相关性：在这项队列研究中，南非限制了13种加工食品的钠在这项粗糙的南非人群中的24HRNA排泄中，这维持了与钠水平相一致的血压降低。</p><p style="color: lightgray"> PMID <a href=https://doi.org/10.1001/jamacardio.2024.5410>：</a> <a href="https://pubmed.ncbi.nlm.nih.gov/39908059/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250205151245&v=2.18.0.post9+e462414">39908059</a> |</p></div> ]>;]]</content:encoded><guid ispermalink="false"> PubMed：39908059</guid><pubDate> Wed, 05 Feb 2025 06:00:00 -0500</pubDate><dc:creator>托马斯·加兹亚诺（Thomas Gaziano）</dc:creator><dc:creator>大卫·卡普恩（David Kapaon）</dc:creator><dc:creator>雅克·d du toit</dc:creator><dc:creator> Nigel J Crowther</dc:creator><dc:creator> Alisha n Wade</dc:creator><dc:creator>六月法比安</dc:creator><dc:creator>Carlos riumallo-herl</dc:creator><dc:creator> F Carla Roberts-Toler</dc:creator><dc:creator> XavierGómez-Olivé</dc:creator><dc:creator>斯蒂芬·托尔曼（Stephen Tollman）</dc:creator><dc:date> 2025-02-05</dc:date><dc:source> JAMA心脏病学</dc:source><dc:title>南非的减少立法和尿钠和血压</dc:title><dc:identifier>PMID：39908059</dc:identifier><dc:identifier> doi：10.1001/jamacardio.2024.5410</dc:identifier></item><item><title>识别高级头部故障的大型门诊C2D阶段 - 行动呼吁</title><link/>https://pubmed.ncbi.nlm.nih.gov/39908057/？ 708114047＆ff = 20250205151245＆v = 2.18.0.post9+e462414<description>结论和相关性：十个关键点总结了研讨会的调查结果，将研究支架作为至关重要的下一步。 。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">重要性：高级门诊心力衰竭（HF）人口包括超越建议的C HF疗法支柱的患者，但仍然可以找到有意义的终身年份。小组接受了堡垒移植的清单或左心室的Y型患者。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">观察：在2022年的Denementer中，国家心脏，肺部和血液研究所召集了一个专家团队，以识别艾滋病人群的知识和研究，限制了每天的症状，并过渡到终止阶段D HF（指定为C2D阶段）总结这3天的研讨会的发现。表型，例如低心输出型，右HF，心脏综合征，富含肝病和脆弱的表型，为Exis Ting和HF提供了不同的目标。术疗法。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论和相关性：十个关键点总结了研讨会的调查结果，将研究支架作为至关重要的下一步。 。</p><p style="color: lightgray"> PMID <a href=https://doi.org/10.1001/jamacardio.2024.5328>：</a> <a href="https://pubmed.ncbi.nlm.nih.gov/39908057/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250205151245&v=2.18.0.post9+e462414">39908057</a> |</p></div> ]>;]]</content:encoded><guid ispermalink="false"> PubMed：39908057</guid><pubDate> Wed, 05 Feb 2025 06:00:00 -0500</pubDate><dc:creator>香农M邓利</dc:creator><dc:creator>肖恩·普莱尼（Sean P Pinney）</dc:creator><dc:creator>阿努拉达·拉拉（Anuradha Lala）</dc:creator><dc:creator> Garrick C Stewart</dc:creator><dc:creator> Colleen McIlvennan</dc:creator><dc:creator>蕾妮·普通（Renee P Wong）</dc:creator><dc:creator>阿兰娜（Alanna）莫里斯（Morris）</dc:creator><dc:creator>弗朗西斯·帕加尼（Francis D Pagani）</dc:creator><dc:creator>拉里（Larry）艾伦（Allen）</dc:creator><dc:creator> Khadijah呼吸</dc:creator><dc:creator>丽贝卡·科格斯塞尔（Rebecca Cogsswell）</dc:creator><dc:creator>莫妮卡·科文（Monica M Colvin）</dc:creator><dc:creator>詹妮弗（Jennifer）是一个牛仔</dc:creator><dc:creator>Stavros G Drakos</dc:creator><dc:creator>劳拉·P·盖尔曼（Laura P Gelfman）</dc:creator><dc:creator> Manreet K Kanwar</dc:creator><dc:creator>迈克尔·基尔南（Michael S Kiernan）</dc:creator><dc:creator>米歇尔·凯特森（Michelle M Kittleson）</dc:creator><dc:creator> Eldrin F Lewis</dc:creator><dc:creator>纳德·莫扎米（Nader Moazami）</dc:creator><dc:creator> Modele Ogunniyi</dc:creator><dc:creator> Ambarian Pandey</dc:creator><dc:creator>约瑟夫·罗杰斯（Joseph G Rogers）</dc:creator><dc:creator> Kurt R Schumacher</dc:creator><dc:creator>马克的屠杀</dc:creator><dc:creator>瑞安·J·特德福德（Ryan J Tedford）</dc:creator><dc:creator> Jeffrey Teuteberg</dc:creator><dc:creator>汉娜是瓦兰丁</dc:creator><dc:creator>Ersilia m Defilippis</dc:creator><dc:creator> Debra D Dixon</dc:creator><dc:creator>杰西卡·罗布斯（Jessica R Golbus）</dc:creator><dc:creator> Gaurav Gulati</dc:creator><dc:creator>托马斯·汉夫（Thomas C Hanff）</dc:creator><dc:creator>斯蒂芬妮·霍</dc:creator><dc:creator>Sabra C Lewsey</dc:creator><dc:creator> Amanda D McCormick</dc:creator><dc:creator> Aditi Nayak</dc:creator><dc:creator>凯瑟琳·芬顿</dc:creator><dc:creator>Lisa Schwartz Longacre</dc:creator><dc:creator> Sujata M Shanbhag</dc:creator><dc:creator> Wendy C Taddei-Peters</dc:creator><dc:creator>林恩·华纳·史蒂文森（Lynne Warner Stevenson）</dc:creator><dc:date> 2025-02-05</dc:date><dc:source> JAMA心脏病学</dc:source><dc:title>识别高级头部故障的大型门诊C2D阶段 - 行动呼吁</dc:title><dc:identifier>PMID：39908057</dc:identifier><dc:identifier> doi：10.1001/jamacardio.2024.5328</dc:identifier></item><item><title>美国和丹麦的老年人的心血管疾病住院</title><link/>https://pubmed.ncbi.nlm.nih.gov/39908055/？ 708114047＆ff = 20250205151245＆v = 2.18.0.post9+e462414<description>结论和相关性：在这种国际跨研究中，与丹麦的心血管造成的心血管疾病。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">重要性：但是，心血管疾病是美国的主要死亡原因，但尚不清楚美国指南针与其他高收入国家（如丹麦和收入）的其他高收入国家的燃烧如何。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：比较心血管（急性心肌梗塞，65岁以上的成年人中的心力衰竭[HF]，整体和收入，美国和丹麦之间。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">设计，设置和参与者：这项基于人群的横断面研究使用了美国和丹麦的国家数据，从2021年1月1日到2022年1月1日。该研究人群包括美国65岁以上的所有Medicare受益人以及丹麦65岁以上的所有成年人。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">主要结果和措施：主要结果是MI，HF和缺血性中风全因死亡率的年龄和标准住院率。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：美国研究人群58 614 110成年人65岁以上（平均[SE]年龄，74.6 [7.7]年； 32 179名女性[54.9％）1 058（2.0％）接受了丹麦研究人口包括1 176 542名成年人65岁或以上（平均[SE]年龄，75.3 [7.1]； 634 217女性[53.9％]），其中16 305（1.4％）因心血管疾病而住院。与丹麦相比（风险大鼠IO [RR]，1.50； 95％CI，1.47-1.52），美国的性别标准化的心血管住院率和相关的30天全因死亡率（RR，1.12 ; 95％CI，1.06-1.17）。与丹麦相比收入成年人（RR，2.38; 95％CI，2.25-2.47），而基于收入的差异的幅度较小（RR，1.45; 95％CI，1.39-1.50）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论和相关性：在这项国际横断面研究中，美国与丹麦的比较中的心血管住院率明显更高。在美国更大。</p><p style="color: lightgray"> PMID <a href=https://doi.org/10.1001/jamacardio.2024.5303>：</a> <a href="https://pubmed.ncbi.nlm.nih.gov/39908055/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250205151245&v=2.18.0.post9+e462414">39908055</a> |</p></div> ]>;]]</content:encoded><guid ispermalink="false"> PubMed：39908055</guid><pubDate> Wed, 05 Feb 2025 06:00:00 -0500</pubDate><dc:creator>弗雷德里克（Frederikke）举行了伯格（Berg）</dc:creator><dc:creator>垫子CHøjbjergLassen</dc:creator><dc:creator> Muthiah Vaduganathan</dc:creator><dc:creator> Gregg C Fonarow</dc:creator><dc:creator>罗伯特·W·耶（Robert W Yeh）</dc:creator><dc:creator> Zhaonian Zheng</dc:creator><dc:creator> Gunnar H Gislason</dc:creator><dc:creator> Tor Biering-Sørensen</dc:creator><dc:creator> Rishi K Wadhera</dc:creator><dc:date> 2025-02-05</dc:date><dc:source> JAMA心脏病学</dc:source><dc:title>美国和丹麦的老年人的心血管疾病住院</dc:title><dc:identifier>PMID：39908055</dc:identifier><dc:identifier> doi：10.1001/jamacardio.2024.5303</dc:identifier></item><item><title>心血管疾病分裂 - 一个高收入国家的故事</title><link/>https://pubmed.ncbi.nlm.nih.gov/39908054/？ 708114047＆ff = 20250205151245＆v = 2.18.0.post9+e462414<description>没有抽象</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol。</p><p><b>没有抽象</b></p><p style="color: lightgray">PMID <a href=https://doi.org/10.1001/jamacardio.2024.5312>：</a> <a href="https://pubmed.ncbi.nlm.nih.gov/39908054/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250205151245&v=2.18.0.post9+e462414">39908054</a> |</p></div> ]>;]]</content:encoded><guid ispermalink="false"> PubMed：39908054</guid><pubDate> Wed, 05 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Sadiya S Khan</dc:creator><dc:date> 2025-02-05</dc:date><dc:source> JAMA心脏病学</dc:source><dc:title>心血管疾病分裂 - 一个高收入国家的故事</dc:title><dc:identifier>PMID：39908054</dc:identifier><dc:identifier> doi：10.1001/jamacardio.2024.5312</dc:identifier></item><item><title>饮食钠和钾富含盐的盐分子 - 临界点？</title><link/> https://pubmed.ncbi.nlm.nih.gov/39908031/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXK wJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250205151245&amp;v=2.18.0.post9+e462414<description>没有抽象</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol。</p><p><b>没有抽象</b></p><p style="color: lightgray">PMID <a href=https://doi.org/10.1001/jamacardio.2024.5430>：</a> <a href="https://pubmed.ncbi.nlm.nih.gov/39908031/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250205151245&v=2.18.0.post9+e462414">39908031</a> |</p></div> ]>;]]</content:encoded><guid ispermalink="false"> PubMed：39908031</guid><pubDate> Wed, 05 Feb 2025 06:00:00 -0500</pubDate><dc:creator>丹尼尔·W·琼斯（Daniel W Jones）</dc:creator><dc:creator>布伦特·恩·埃根（Brent M Egan）</dc:creator><dc:creator>丹尼尔·托马斯·拉克兰（Daniel Thomas Lackland）</dc:creator><dc:date> 2025-02-05</dc:date><dc:source> JAMA心脏病学</dc:source><dc:title>饮食钠和钾富含盐的盐分子 - 临界点？</dc:title><dc:identifier> PMID：39908031</dc:identifier><dc:identifier> doi：10.1001/jamacardio.2024.5430</dc:identifier></item><item><title>权限错误</title><link/>https://pubmed.ncbi.nlm.nih.gov/39908030/？ 08114047＆ff = 20250205151245＆v = 2.18.0.post9+e462414<description>没有抽象</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol。</p><p><b>没有抽象</b></p><p style="color: lightgray">PMID <a href=https://doi.org/10.1001/jamacardio.2025.0001>：</a> <a href="https://pubmed.ncbi.nlm.nih.gov/39908030/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250205151245&v=2.18.0.post9+e462414">39908030</a> |</p></div> ]>;]]</content:encoded><guid ispermalink="false"> PubMed：39908030</guid><pubDate> Wed, 05 Feb 2025 06:00:00 -0500</pubDate><dc:date> 2025-02-05</dc:date><dc:source> JAMA心脏病学</dc:source><dc:title>权限错误</dc:title><dc:identifier>PMID：39908030</dc:identifier><dc:identifier> doi：10.1001/jamacardio.2025.0001</dc:identifier></item><item><title>盐变电站和复发性中风和死亡：一项随机临床试验</title><link/>https://pubmed.ncbi.nlm.nih.gov/39908026/？ 708114047＆ff = 20250205151245＆v = 2.18.0.post9+e462414<description>结论和相关性：这项集群试验的结果证明了盐的替代是安全的，以及中风复发的风险降低了，这突显了Scaltis从Scaltis中获得很大的健康，从而使这种低成本的人遇到了卒中。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">重要性：盐替代物对中风患者复发性中风和死亡率的直接影响尚不清楚。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：替代品与常规盐的影响对patieth之间的ctity呈现。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">设计，环境和参与者：盐替代和中风研究（SSAS），一个开放标签的，簇的随机临床试验，中国村庄（群集）。从2023年11月至2024年8月分析了数据。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">参与者：被分配使用盐替代品，由75％氯化钠和孔盐组成。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">主要结果和措施：主要结果是复发性中风。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：排除了5746名没有中风的基线历史的人，包括15例中风患者（平均[SD]年龄，64.1 [8.8]年； 6999 [45.9％] FE男性； 8250雄性[54.1％]）中值（IQR）跟随-61.2（60.9-61.6）月，系统差异的平均差异为-2.05 mm Hg（95％CI，-3.03至-1.08 mm Hg），为2735 Recurrent Prots Everty（691）记录了致命的和2044个非致命的）和3242人死亡。对出血性中风的影响（相对修订，30％； P = .002），对中风相关的死亡有更大的影响（相对修复21％； P = .01） 95％CI，0.74-1.38; </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论和相关性：这项集群试验的结果证明了盐的替代是安全的，以及中风复发的风险降低了，这突显了Scaltis从Scaltis中获得的大量健康，从而使这种低成本的人遇到了风格。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">试验注册：ClinicalTrials.gov标识符：NCT02092090。</p><p style="color: lightgray"> PMID <a href=https://doi.org/10.1001/jamacardio.2024.5417>：</a> <a href="https://pubmed.ncbi.nlm.nih.gov/39908026/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250205151245&v=2.18.0.post9+e462414">39908026</a> |</p></div> ]>;]]</content:encoded><guid ispermalink="false"> PubMed：39908026</guid><pubDate> Wed, 05 Feb 2025 06:00:00 -0500</pubDate><dc:creator> xiong ding</dc:creator><dc:creator> Xinyi Zhang</dc:creator><dc:creator>黄色的黄</dc:creator><dc:creator>上学Xiong</dc:creator><dc:creator> li</dc:creator><dc:creator> Yi Zhao</dc:creator><dc:creator> Bo Zhou</dc:creator><dc:creator> Xuejun Yin</dc:creator><dc:creator> bingqing xu</dc:creator><dc:creator> Yanfeng Wu</dc:creator><dc:creator>布鲁斯·尼尔</dc:creator><dc:creator>Maoyi Tian</dc:creator><dc:creator> lijing l yan</dc:creator><dc:date> 2025-02-05</dc:date><dc:source> JAMA心脏病学</dc:source><dc:title>盐变电站和复发性中风和死亡：一项随机临床试验</dc:title><dc:identifier>PMID：39908026</dc:identifier><dc:identifier> doi：10.1001/jamacardio.2024.5417</dc:identifier></item><item><title>心力衰竭中的贫血，神经激活和心肌铁的耗竭：恶性循环会破裂吗？</title><link/> https://pubmed.ncbi.nlm.nih.gov/39907696/？ 708114047＆ff = 20250205151245＆v = 2.18.0.post9+e462414<description>没有抽象</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2025 2月5日：Ehae798：10.1093/Eurheartj/ehae798。</p><p><b>没有抽象</b></p><p style="color: lightgray">PMID <a href=https://doi.org/10.1093/eurheartj/ehae798>：</a> <a href="https://pubmed.ncbi.nlm.nih.gov/39907696/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250205151245&v=2.18.0.post9+e462414">39907696</a> |</p></div> ]>;]]</content:encoded><guid ispermalink="false"> PubMed：39907696</guid><pubDate> Wed, 05 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Samira Lakhal-Littleton</dc:creator><dc:date> 2025-02-05</dc:date><dc:source>欧洲心脏期刊</dc:source><dc:title>心力衰竭中的贫血，神经激活和心肌铁的耗竭：恶性循环会破裂吗？</dc:title><dc:identifier> PMID：39907696</dc:identifier><dc:identifier> doi：10.1093/eurheartj/ehae798</dc:identifier></item><item><title>贫血预测铁均匀的失调，随着EMP Atropism-FE试验的减少，心力衰竭对雌激素的反应</title><link/>https://pubmed.ncbi.nlm.nih.gov/39907687/？ 708114047＆ff = 20250205151245＆v = 2.18.0.post9+e462414<description>结论：鉴于这种反相关性，iflozin增加了IFLOZIN的含量障碍，可以增加麦克风，并减少去甲肾上腺素。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2025 2月5日：Ehae917。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景和目的：钠 - 葡萄糖共转运蛋白2影响心力衰竭患者的铁代谢，但机制是事后分析探索了铁稳态，心脏结构/功能，运动能力，HA ematopoiesis和基线时的交感神经以及效果之间的相互关系伴有贫血状态在伴侣研究参与者中，用empagliflozin vs.安慰剂治疗6个月。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：心肌铁含量（麦克风，通过心脏磁共振T2*成像估算），左心室（LV）体积和LV射血分数（LVEF），运动能力，实验室铁标记（LIM），血红蛋白/血红蛋白/血蛋白，血质，红细胞蛋白，嗜血杆菌和血浆蛋白和血浆在基线和6个月时确定去甲肾上腺素。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：基线，24/80名参与者（30％）。红细胞生成素（p = .040）和去甲肾上腺素（p = .016）。血红蛋白/血细胞比例（P &lt;.001）。耗尽和交感神观。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：输入/可用性可能是共享的肌肉症，心力衰竭的止血作用限制，在患有贫血的患者中会改善，并随着emagliflozin的形式改善。帮助解释SGLT2I疗法的潜水心脏和系统性益处。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">临床试验注册：NCT03485222（www.clinicaltrials.gov）。</p><p style="color: lightgray"> PMID <a href=https://doi.org/10.1093/eurheartj/ehae917>：</a> <a href="https://pubmed.ncbi.nlm.nih.gov/39907687/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250205151245&v=2.18.0.post9+e462414">39907687</a> |</p></div> ]>;]]</content:encoded><guid ispermalink="false"> PubMed：39907687</guid><pubDate> Wed, 05 Feb 2025 06:00:00 -0500</pubDate><dc:creator>克里斯蒂安·艾格曼（Christiane E Angermann）</dc:creator><dc:creator>苏珊·塞纳（Susanne Sehner）</dc:creator><dc:creator>路易莎女士格哈特</dc:creator><dc:creator>Carlos G Santos-Gallego</dc:creator><dc:creator> Juan Antonio Requena-Ibanez</dc:creator><dc:creator> Tanja Zeller</dc:creator><dc:creator>克里斯托夫·马克（Christoph Maack）</dc:creator><dc:creator>哈维尔·桑兹（Javier Sanz）</dc:creator><dc:creator> Stefan Frantz</dc:creator><dc:creator> Georg Ertl</dc:creator><dc:creator> Juan J Badimon</dc:creator><dc:date> 2025-02-05</dc:date><dc:source>欧洲心脏期刊</dc:source><dc:title>贫血预测铁同源性失调，并通过减少的射血分数调节对心力衰竭的反应：EMP Atropism-FE试验</dc:title><dc:identifier>PMID：39907687</dc:identifier><dc:identifier> doi：10.1093/eurheartj/ehae917</dc:identifier></item><item><title> &lt;em>;流通期刊家族的亮点</title><link/>https://pubmed.ncbi.nlm.nih.gov/39907595/？ 708114047＆ff = 20250205151245＆v = 2.18.0.post9+e462414<description>没有抽象</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>循环</b>。2024年12月3日； 150（23）：1898-1903。</p><p><b>没有抽象</b></p><p style="color: lightgray">PMID <a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072974>：</a> <a href="https://pubmed.ncbi.nlm.nih.gov/39907595/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250205151245&v=2.18.0.post9+e462414">39907595</a> |</p></div> ]>;]]</content:encoded><guid ispermalink="false"> PubMed：39907595</guid><pubDate> Wed, 05 Feb 2025 06:00:00 -0500</pubDate><dc:date> 2025-02-05</dc:date><dc:source>循环</dc:source><dc:title>&lt;em>;流通期刊家族的亮点</dc:title><dc:identifier>PMID：39907595</dc:identifier><dc:identifier> doi：10.1161/CirculationAha.124.072974</dc:identifier></item><item><title>逐步临时和系统的双层策略，用于治疗真正的左主冠状动脉分叉病变</title><link/>https://pubmed.ncbi.nlm.nih.gov/39907022/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250205151245&amp;v=2.18.0.post9+e462414<description>结论：在左手分叉冠状动脉疾病的欧洲人群中，需要在3年的逐步临时双层策略之间进行重大不良diofastival事件。对于非复杂性左主叉冠冠状动脉国际。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>循环</b>。2025年2月5日。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：与系统的双固定方法相比，对真实左主分叉病变的最佳冠状动脉施加技术旨在评估逐步临时策略的临床结果。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：EBC Main是一个随机，研究者发射的，开放标签的，多中心的，平行组试验，在35个pean国家中进行了467个参与者的冠状动脉干预，以随机地与逐步的临时策略（N = 230）或前期双期方法（n = 237）。所有心肌梗死。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在3年中，主要终点是230<i>个</i>逐步临时的（23.5％）和237个（29.5％）O，0.75 [95％CI，0.53-1.07]；全因死亡率的显着差异（10.0％对13.1 <i>％</i> ）。 <i>）</i> <i>。</i> = 0.005），具有较小的血管（直径&lt;3.25毫米）和较短的病变（长度&lt;10 mm），有利于临时方法。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：在左手分叉冠状动脉疾病的欧洲人群中，需要在3年的逐步临时双层策略之间进行重大不良diofastival事件。对于非复杂性左主叉冠冠状动脉国际。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">注册：URL：https：//www.clinicaltrials.gov;</p><p style="color: lightgray"> PMID <a href=https://doi.org/10.1161/CIRCULATIONAHA.124.071153>：</a> <a href="https://pubmed.ncbi.nlm.nih.gov/39907022/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250205151245&v=2.18.0.post9+e462414">39907022</a> |</p></div> ]>;]]</content:encoded><guid ispermalink="false"> PubMed：39907022</guid><pubDate> Wed, 05 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Sandeep Arunothayaraj</dc:creator><dc:creator> Mohaned Egred</dc:creator><dc:creator> Adrian P Banning</dc:creator><dc:creator>菲利普·布鲁内尔（Philippe Brunel）</dc:creator><dc:creator> Miroslaw Ferenc</dc:creator><dc:creator>托马斯·霍瓦斯（Thomas Hovasse）</dc:creator><dc:creator> Adrian Wlodarczak</dc:creator><dc:creator>曼努埃尔·潘（Manuel Pan）</dc:creator><dc:creator>托马斯·施密茨（Thomas Schmitz）</dc:creator><dc:creator>马克·西尔维斯特里（Marc Silvestri）</dc:creator><dc:creator>安德烈·埃格利斯（Andreis Erglis）</dc:creator><dc:creator> Evgeny Kretov</dc:creator><dc:creator> Jens Flensted Lassen</dc:creator><dc:creator> Alaide Chieffo</dc:creator><dc:creator> ThierryLefèvre</dc:creator><dc:creator> Francesco Burzotta</dc:creator><dc:creator>詹姆斯·科克本</dc:creator><dc:creator>奥利维尔·达雷蒙特（Olivier Darremont）</dc:creator><dc:creator> Goran Stankovic</dc:creator><dc:creator>玛丽·克劳德·莫里斯（Marie-Claude Morice）</dc:creator><dc:creator>伊夫·卢瓦德（Yves Louvard）</dc:creator><dc:creator>大卫·希尔迪克·史密斯（David Hildick-Smith）</dc:creator><dc:date> 2025-02-05</dc:date><dc:source>循环</dc:source><dc:title>逐步临时和系统的双层策略，用于治疗真正的左主冠状动脉分叉病变</dc:title><dc:identifier>PMID：39907022</dc:identifier><dc:identifier> doi：10.1161/CirculationAha.124.071153</dc:identifier></item><item><title> CD4 &lt;Sup>;+&lt;/sup>; T CD4 D在内皮NADPH氧化酶1中增加</title><link/>https://pubmed.ncbi.nlm.nih.gov/39907014/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250205151245&amp;v=2.18.0.post9+e462414<description>结论：我们首先证明了表达Hival蛋白的CD4^（+）T细胞通过血管NOX1中的IL-1α-Medias ES诱导高血压，这会损害男性和女性的其他功能。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>循环</b>。2025年2月5日。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：Althooth组合抗逆转录病毒疗法增加了HIV的生活，这导致了高血压的患病率，其原因是CD4 <sup>+</sup> T淋巴细胞中的HIV中的HIV。高血压和内皮依赖性受损仍未定义。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：表达病毒蛋白的CD4 <sup>+</sup> T细胞使用TE G26小鼠模型有助于内皮功能障碍和高血压。 BMT），CD4 <sup>+</sup> T细胞的过继转移和从HIV患者中丢弃的主动脉标本。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：我们报道了接收BMT（TG26→WT）的TG26小鼠或TG26小鼠的CD4 <sup>+</sup> T细胞表现出<sup>暗示</sup>性的ENDENDENDENDENDENDENDENDENDENDENDENDENDENDENDENDENDENDENDENDENDENDENDENDENDENDENTAIL，对话，从WT小鼠中进行BMT。 T细胞耗尽的TG26小鼠的内皮内皮FUOD压力揭示了TG26小鼠，TG26 26 CD4 <sup>+</sup> T细胞始终表现出高介粒细胞介素1α（IL-1α）水平，而其他细胞因子不显着增加，WT小鼠降低了TG26小鼠的IL-1α TG26小鼠的<sup>水平</sup><sup>。</sup> 1α中和抗体。 TG26 BMT i的内皮依赖性弛豫和高血压。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：我们首先证明CD4 <sup>+</sup> T细胞通过IL-1α介导的增加的血管NOX1表达HIV病毒蛋白诱导高血压，这会损害男性和女性的其他功能。</p><p style="color: lightgray"> PMID <a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070538>：</a> <a href="https://pubmed.ncbi.nlm.nih.gov/39907014/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250205151245&v=2.18.0.post9+e462414">39907014</a> |</p></div> ]>;]]</content:encoded><guid ispermalink="false"> PubMed：39907014</guid><pubDate> Wed, 05 Feb 2025 06:00:00 -0500</pubDate><dc:creator>泰勒·克雷斯（Taylor C Kress）</dc:creator><dc:creator> Candee T Barris</dc:creator><dc:creator> laszlo kovacs</dc:creator><dc:creator> Beryl N Khakina</dc:creator><dc:creator> Coleton R Jordan</dc:creator><dc:creator> Thiago Bruder-Nascimento</dc:creator><dc:creator> David W Stepp</dc:creator><dc:creator>罗杰·麦克阿瑟（Rodger MacArthur）</dc:creator><dc:creator> Vijay S Patel</dc:creator><dc:creator> Jie Chen</dc:creator><dc:creator> Rafal Pacholczyk</dc:creator><dc:creator>西蒙妮·肯纳德（Simone Kennard）</dc:creator><dc:creator> Eric J Belin de Chantemle</dc:creator><dc:date> 2025-02-05</dc:date><dc:source>循环</dc:source><dc:title>CD4 &lt;Sup>;+&lt;/sup>; T CD4 D在内皮NADPH氧化酶1中增加</dc:title><dc:identifier>PMID：39907014</dc:identifier><dc:identifier> doi：10.1161/CirculationAha.124.070538</dc:identifier></item><item><title> Irbesartan在Celiprololol治疗的Pascular Ehlers-Danlos综合征中的功效</title><link/>https://pubmed.ncbi.nlm.nih.gov/39906986/？ 708114047＆ff = 20250205151245＆v = 2.18.0.post9+e462414<description>结论：与安慰剂相比，Irbesartan降低了在背景celiprololol治疗的血管LERS-DANLOS综合征患者中严重症状动脉动脉事件的风险。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>循环</b>。2025年2月5日。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：血管ehlers-danlos综合征是一种罕见的遗传疾病，其特征是III胶原蛋白，而动脉疾病和死亡率迄今为止。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：一项多件，安慰剂对照试验在患有稳定的背景celiprolol疗法的血管生成蛋白II受体阻滞剂Baseartan的疗效和安全性。复合材料的主要结果被定义为任何致命或非致命人工事件，或者是通过系统到pel-Pelvis Compure Compure Compure Compoich phensograghy Changiography检测到的任何新的或恶化的动脉病变 - 事件分析。になったんです。英语：您可以做的第一件事是找到最好的方法。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：29名参与者（62％的女性； 40.3±11.3岁）被随机分配给Irbesartan，28岁（64％的女性； 40.7±11.0岁的年龄）随机分配给安慰剂。在29名患者（27.6％）接受IRBESARTAN的患者中，28例患者中有15例（53.6％）接受安慰剂<i>（</i>危险比，0.42 [95％CI，0.17，0.99]他发生反复发生的症状性或无症状的风险，而与安慰剂相比，与安慰剂相比（95％CI，0.19，0.68]； <i>p</i> = 0.002） <i>。</i>在4例患者中下降。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：与安慰剂相比，Irbesartan降低了在背景celiprololol治疗的血管LERS-DANLOS综合征患者中严重症状动脉动脉事件的风险。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">注册：URL：https：//www.clinicaltrials.gov;</p><p style="color: lightgray"> PMID <a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072849>：</a> <a href="https://pubmed.ncbi.nlm.nih.gov/39906986/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250205151245&v=2.18.0.post9+e462414">39906986</a> |</p></div> ]>;]]</content:encoded><guid ispermalink="false"> PubMed：39906986</guid><pubDate> Wed, 05 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Xavier Jeunemaitre</dc:creator><dc:creator> Elie Mousseaux</dc:creator><dc:creator>迈克尔·弗兰克</dc:creator><dc:creator>萨尔玛·阿德姆</dc:creator><dc:creator>Francesca Pitocco</dc:creator><dc:creator>克拉丽丝·比隆</dc:creator><dc:creator>Molka Ben Yakhlef</dc:creator><dc:creator>穆罕默德·埃尔·哈希米（Mohamed El Hachmi）</dc:creator><dc:creator> Alessandra Bura-Rivière</dc:creator><dc:creator> François-XavierLapébie</dc:creator><dc:creator>克莱尔·勒（Claire le Hello）</dc:creator><dc:creator>达米安·莱内尔（Damien Laneelle）</dc:creator><dc:creator>克里斯托夫·塞敦库（Christophe Seinturier）</dc:creator><dc:creator>克劳斯·迪特里奇（Klaus Dieterich）</dc:creator><dc:creator>马克·兰伯特</dc:creator><dc:creator>Sophie Dupuis-Girlod</dc:creator><dc:creator>斯蒂芬·齐里（Stephane Zuily）</dc:creator><dc:creator>劳伦斯·巴尔托利耶尔</dc:creator><dc:creator>卡琳·布隆</dc:creator><dc:creator>皮尔里克·亨尼顿（Pierrick Henneton）</dc:creator><dc:creator> Estelle Lu</dc:creator><dc:creator>尼古拉斯·丹纳里（NicolasDenarié）</dc:creator><dc:creator>皮埃尔·布托伊里（Pierre Boutouyrie）</dc:creator><dc:creator> Tristan Mirault</dc:creator><dc:creator>吉尔斯·查尔利尔（Gilles Chatellier）</dc:creator><dc:creator>米歇尔·阿齐兹（Michel Azizi）</dc:creator><dc:date> 2025-02-05</dc:date><dc:source>循环</dc:source><dc:title>Irbesartan在Celiprololol治疗的Pascular Ehlers-Danlos综合征中的功效</dc:title><dc:identifier>PMID：39906986</dc:identifier><dc:identifier> doi：10.1161/CirculationAha.124.072849</dc:identifier></item><item><title>临床效用和预测心血管疾病的多基因风险评分的实施</title><link/>https://pubmed.ncbi.nlm.nih.gov/39906985/？ 8114047＆ff = 20250205151245＆v = 2.18.0.post9+e462414<description>全基因组关联研究与心血管疾病相关的数百种遗传变异（CVD）可以在单个度量标准中捕获这些信息，并有望在CVD风险中使用。个人是裸露的生活。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2025 2月5日：Ehae649。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">全基因组关联研究与心血管疾病相关的数百种遗传变异（CVD）可以在单个度量标准中捕获这些信息，并有望在CVD风险中使用。个人在常规的临床实践中使用了暴露的生活。迄今为止，出于疾病的目的，他们在C. VD中的作用进行了预测。 l社区可以将未来的公关过渡到常规的临床护理。</p><p style="color: lightgray"> PMID <a href=https://doi.org/10.1093/eurheartj/ehae649>：</a> <a href="https://pubmed.ncbi.nlm.nih.gov/39906985/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250205151245&v=2.18.0.post9+e462414">39906985</a> |</p></div> ]>;]]</content:encoded><guid ispermalink="false"> PubMed：39906985</guid><pubDate> Wed, 05 Feb 2025 06:00:00 -0500</pubDate><dc:creator>赫里伯特·尚克特（Heribert Schunkert）</dc:creator><dc:creator> Emanuele di Angelantonio</dc:creator><dc:creator>迈克尔·乌诺耶（Michael Inouye）</dc:creator><dc:creator> Riyaz的Patel</dc:creator><dc:creator> Samuli Ripatti</dc:creator><dc:creator>伊丽莎白·加宽</dc:creator><dc:creator>萨斯基亚C桑德森</dc:creator><dc:creator>胡安·帕勃罗·卡斯基（Juan Pablo Kaski）</dc:creator><dc:creator>约翰·W·梅切沃伊（John W McEvoy）</dc:creator><dc:creator> Panos Vardas</dc:creator><dc:creator>安吉拉·伍德</dc:creator><dc:creator>Victor Aboyans</dc:creator><dc:creator> Vassilios S Vassiliou</dc:creator><dc:creator>弗兰克·LJ Visseren</dc:creator><dc:creator>路易斯·洛佩斯</dc:creator><dc:creator>佩里·埃利奥特（Perry Eliott）</dc:creator><dc:creator> Maryam Kavousi</dc:creator><dc:date> 2025-02-05</dc:date><dc:source>欧洲心脏期刊</dc:source><dc:title>临床效用和预测心血管疾病的多基因风险评分的实施</dc:title><dc:identifier>PMID：39906985</dc:identifier><dc:identifier> doi：10.1093/eurheartj/ehae649</dc:identifier></item><item><title>用于诊断Takotsubo综合征的心脏生物标志物：保持简单吗？</title><link/> https://pubmed.ncbi.nlm.nih.gov/39902777/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250205151245&amp;v=2.18.0.post9+e462414<description>没有抽象</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2025 2月4日：Ehae765：10.1093/EurheartJ/Ehae765。</p><p><b>没有抽象</b></p><p style="color: lightgray">PMID <a href=https://doi.org/10.1093/eurheartj/ehae765>：</a> <a href="https://pubmed.ncbi.nlm.nih.gov/39902777/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250205151245&v=2.18.0.post9+e462414">39902777</a> |</p></div> ]>;]]</content:encoded><guid ispermalink="false"> PubMed：39902777</guid><pubDate> Tue, 04 Feb 2025 06:00:00 -0500</pubDate><dc:creator>奥利维尔·加赫（Olivier Gach）</dc:creator><dc:creator>查尔斯·皮雷特（Charles Pirlet）</dc:creator><dc:date> 2025-02-04</dc:date><dc:source>欧洲心脏期刊</dc:source><dc:title>用于诊断Takotsubo综合征的心脏生物标志物：保持简单吗？</dc:title><dc:identifier> PMID：39902777</dc:identifier><dc:identifier> doi：10.1093/eurheartj/ehae765</dc:identifier></item><item><title>预测性心词：将单细胞多构想转化为个性化医学工具</title><link/>https://pubmed.ncbi.nlm.nih.gov/39900732/？ 08114047＆ff = 20250205151245＆v = 2.18.0.post9+e462414<description>没有抽象</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Nat Rev Cardiol。</p><p><b>没有抽象</b></p><p style="color: lightgray">PMID <a href=https://doi.org/10.1038/s41569-025-01132-3>：</a> <a href="https://pubmed.ncbi.nlm.nih.gov/39900732/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250205151245&v=2.18.0.post9+e462414">39900732</a> |</p></div> ]>;]]</content:encoded><guid ispermalink="false"> PubMed：39900732</guid><pubDate> Mon, 03 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Kami Pekayvaz</dc:creator><dc:creator>马蒂亚斯·海尼格（Matthias Heinig）</dc:creator><dc:creator> Konstantin Stark</dc:creator><dc:date> 2025-02-03</dc:date><dc:source>自然评论</dc:source><dc:title>预测性心词：将单细胞多构想转化为个性化医学工具</dc:title><dc:identifier>PMID：39900732</dc:identifier><dc:identifier> doi：10.1038/s41569-025-01132-3</dc:identifier></item><item><title>临床证据的胜利：国际肺栓塞治疗国际策略的首次面对面试验</title><link/>https://pubmed.ncbi.nlm.nih.gov/39899637/？ 708114047＆ff = 20250205151245＆v = 2.18.0.post9+e462414<description>没有抽象</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>循环</b>。2025年2月4日；</p><p><b>没有抽象</b></p><p style="color: lightgray">PMID <a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072972>：</a> <a href="https://pubmed.ncbi.nlm.nih.gov/39899637/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250205151245&v=2.18.0.post9+e462414">39899637</a> |</p></div> ]>;]]</content:encoded><guid ispermalink="false"> PubMed：39899637</guid><pubDate> Mon, 03 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Sunil V Rao</dc:creator><dc:creator> J Antonio T Gutierrez</dc:creator><dc:date> 2025-02-03</dc:date><dc:source>循环</dc:source><dc:title>临床证据的胜利：国际肺栓塞治疗国际策略的首次面对面试验</dc:title><dc:identifier>PMID：39899637</dc:identifier><dc:identifier> doi:10.1161/CIRCULATIONAHA.124.072972</dc:identifier></item><item><title>如果我们相信我们对精密医学的看法，请测量载脂蛋白B</title><link/> https://pubmed.ncbi.nlm.nih.gov/39899636/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250205151245&amp;v=2.18.0.post9+e462414<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Circulation</b> . 2025 Feb 4;151(5):257-259. doi: 10.1161/CIRCULATIONAHA.123.067559. Epub 2025 Feb 3.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/39899636/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250205151245&v=2.18.0.post9+e462414">39899636</a> | DOI: <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067559>10.1161/CIRCULATIONAHA.123.067559</a></p></div> ]>;]]</content:encoded><guid ispermalink="false"> PubMed：39899636</guid><pubDate> Mon, 03 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Anna Wolska</dc:creator><dc:creator> Donald M Lloyd-Jones</dc:creator><dc:creator> Alan T Remaley</dc:creator><dc:date> 2025-02-03</dc:date><dc:source>循环</dc:source><dc:title>如果我们相信我们对精密医学的看法，请测量载脂蛋白B</dc:title><dc:identifier> PMID：39899636</dc:identifier><dc:identifier> doi:10.1161/CIRCULATIONAHA.123.067559</dc:identifier></item><item><title> Wang和Peng Legarding文章的信：“病毒引起的Accentory遇险综合征通过心脏中引起的Ory反应引起心肌病”</title><link/> https://pubmed.ncbi.nlm.nih.gov/39899635/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250205151245&amp;v=2.18.0.post9+e462414<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Circulation</b> . 2025 Feb 4;151(5):e33-e34. doi: 10.1161/CIRCULATIONAHA.124.069798. Epub 2025 Feb 3.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/39899635/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250205151245&v=2.18.0.post9+e462414">39899635</a> | DOI: <a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069798>10.1161/CIRCULATIONAHA.124.069798</a></p></div> ]>;]]</content:encoded><guid ispermalink="false"> pubmed:39899635</guid><pubDate> Mon, 03 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Xiang Wang</dc:creator><dc:creator> Xiaoping Peng</dc:creator><dc:date> 2025-02-03</dc:date><dc:source>循环</dc:source><dc:title>Wang和Peng Legarding文章的信：“病毒引起的Accentory遇险综合征通过心脏中引起的Ory反应引起心肌病”</dc:title><dc:identifier> pmid:39899635</dc:identifier><dc:identifier> doi:10.1161/CIRCULATIONAHA.124.069798</dc:identifier></item><item><title> Measuring Representativeness in Clinical Trials</title><link/> https://pubmed.ncbi.nlm.nih.gov/39899634/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250205151245&amp;v=2.18.0.post9+e462414<description> Representativeness in randomized clinical trials remains a critical concern, affecting the external validity of trial results, equitable access to the risks and benefits of research participation, and public trust in clinical research. Although representative participation by members of groups traditionally underrepresented in clinical trials is just a surrogate for true diversity, equity, inclusion, and belonging in clinical trials, it can be quantified, allowing stakeholders to add empirical... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Circulation</b> . 2025 Feb 4;151(5):318-330. doi: 10.1161/CIRCULATIONAHA.124.070299. Epub 2025 Feb 3.</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> Representativeness in randomized clinical trials remains a critical concern, affecting the external validity of trial results, equitable access to the risks and benefits of research participation, and public trust in clinical research. Although representative participation by members of groups traditionally underrepresented in clinical trials is just a surrogate for true diversity, equity, inclusion, and belonging in clinical trials, it can be quantified, allowing stakeholders to add empirical rigor to diversity, equity, inclusion, and belonging efforts. Multiple ways to measure representativeness have been proposed, including the participation-to-prevalence ratio, raw participation proportions or numbers for relevant subgroups, and enrollment fraction for relevant subgroups. These methods have strengths and weaknesses and may be appropriate to report in certain circumstances, depending on why stakeholders seek to assess representativeness. Stakeholders-including regulatory agencies, journal editors, clinical trial investigators, and trial sponsors-may use quantitative measures of representativeness to establish trial enrollment standards, monitor equitable participation in ongoing trials, and condition funding or drug or device approval on achieving specific representativeness targets. However, using quantitative measures of representativeness in this way could have unintended consequences, including researchers &quot;gaming&quot; recruitment strategies to meet target numbers, overlooking nuanced variations within communities, and potentially incentivizing problematic and exploitative recruitment strategies. Although no single method of measuring representativeness offers a comprehensive solution for increasing diversity, equity, inclusion, and belonging in all randomized clinical trials, a carefully designed, multifaceted approach to measuring representativeness may provide stakeholders with useful perspectives for measuring progress in increasing the diversity of clinical trial participation. For stakeholders seeking a single number to assess the representativeness of a trial enrolling patients with a disease state with well-delineated demographics, the participation-to-prevalence ratio is ideal; however, for a more nuanced view of representativeness, the combination of enrollment fraction in subgroups of relevance plus a full report of the demographics of patients approached for enrollment may be more appropriate.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/39899634/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250205151245&v=2.18.0.post9+e462414">39899634</a> | DOI: <a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070299>10.1161/CIRCULATIONAHA.124.070299</a></p></div> ]>;]]</content:encoded><guid ispermalink="false"> pubmed:39899634</guid><pubDate> Mon, 03 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Allen Sanyi</dc:creator><dc:creator> Samuel Byiringiro</dc:creator><dc:creator> Sanaz Dabiri</dc:creator><dc:creator> Mireille Jacobson</dc:creator><dc:creator> Amanda Boyd</dc:creator><dc:creator> Modele O Ogunniyi</dc:creator><dc:creator> Alanna A Morris</dc:creator><dc:creator> Rachel Kohn</dc:creator><dc:creator> Neal W Dickert</dc:creator><dc:creator> Meghan B Lane-Fall</dc:creator><dc:creator> Eldrin F Lewis</dc:creator><dc:creator> Scott D Halpern</dc:creator><dc:creator> Alexander C Fanaroff</dc:creator><dc:date> 2025-02-03</dc:date><dc:source>循环</dc:source><dc:title>Measuring Representativeness in Clinical Trials</dc:title><dc:identifier> pmid:39899634</dc:identifier><dc:identifier> doi:10.1161/CIRCULATIONAHA.124.070299</dc:identifier></item><item><title> Risk of Atrial Fibrillation After Hemorrhagic Stroke: A Nationwide Cohort Study With Propensity Score Matching</title><link/> https://pubmed.ncbi.nlm.nih.gov/39899633/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250205151245&amp;v=2.18.0.post9+e462414<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Circulation</b> . 2025 Feb 4;151(5):331-333. doi: 10.1161/CIRCULATIONAHA.124.070662. Epub 2025 Feb 3.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/39899633/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250205151245&v=2.18.0.post9+e462414">39899633</a> | DOI: <a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070662>10.1161/CIRCULATIONAHA.124.070662</a></p></div> ]>;]]</content:encoded><guid ispermalink="false"> pubmed:39899633</guid><pubDate> Mon, 03 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Jihun Kang</dc:creator><dc:creator> Jung Eun Yoo</dc:creator><dc:creator> Byeoung-Jun Jeon</dc:creator><dc:creator> Sung Il Im</dc:creator><dc:creator> Bongseong Kim</dc:creator><dc:creator> Won Hyuk Chang</dc:creator><dc:creator> Kyungdo Han</dc:creator><dc:creator> Dong Wook Shin</dc:creator><dc:date> 2025-02-03</dc:date><dc:source>循环</dc:source><dc:title>Risk of Atrial Fibrillation After Hemorrhagic Stroke: A Nationwide Cohort Study With Propensity Score Matching</dc:title><dc:identifier> pmid:39899633</dc:identifier><dc:identifier> doi:10.1161/CIRCULATIONAHA.124.070662</dc:identifier></item></channel></rss>